Filter posts

RegeneRx’s TB4 shows functional recovery in MS animal model

RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) announces significant improvement in neurological functional recovery after TB4 treatment …

Novelos announces $1 million NIH Grant

Novelos Therapeutics, Inc. (OTCBB: NVLT) was awarded a $950,371 competitive grant by the National Institutes …

Positive Results in Plague Study

Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced results from a primate study …

Vical Licensee Completes Enrollment in Phase 3 Trial

Vical Incorporated (Nasdaq:VICL) licensee, sanofi-aventis, has completed enrollment in a 500-patient Phase 3 clinical trial …

Plexxikon Announces PLX4032 Phase I Clinical Trial Results

Plexxikon Inc. reports positive clinical data from a Phase 1 extension study of PLX4032 (RG7204) …

Peptimmune Collaborates with Walter Reed on Dengue Virus Vaccine

Peptimmune, Inc. has formed a collaboration with the Walter Reed Army Institute of Research and …

Dendreon’s PROVENGE making regulatory and commercialization progress

Dendreon Corporation (Nasdaq: DNDN) today reported regulatory and commercialization progress for PROVENGE® (sipuleucel-T), the company’s …

Inovio CEO Speaks at MIT Conference

Dr. J. Joseph Kim, CEO of Inovio Biomedical Corporation (NYSE Amex: INO), presented keynote remarks …

Xoma to develop antibody for H1N1 and H5N1

XOMA Ltd. (Nasdaq:XOMA) is developing an antibody that has been shown by Dana-Farber Cancer Institute …

The latest from GlobeImmune

Interview with Timothy C. Rodell, M.D., GlobeImmune CEO & President: Can you describe the top …